Edition:
India

Recro Pharma Inc (REPH.OQ)

REPH.OQ on NASDAQ Stock Exchange Capital Market

7.21USD
24 Sep 2018
Change (% chg)

$0.16 (+2.27%)
Prev Close
$7.05
Open
$7.05
Day's High
$7.33
Day's Low
$7.05
Volume
28,754
Avg. Vol
68,271
52-wk High
$13.05
52-wk Low
$4.78

Latest Key Developments (Source: Significant Developments)

Recro Pharma - ‍Ryan Lake Promoted To CFO
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Recro Pharma Inc ::RECRO PHARMA INC - ‍RYAN D. LAKE HAS BEEN PROMOTED TO CHIEF FINANCIAL OFFICER​.  Full Article

Recro Pharma Says Entered Into A Sales Agreement With Cowen And Co‍​
Saturday, 30 Dec 2017 

Dec 29 (Reuters) - Recro Pharma Inc ::RECRO PHARMA INC - ENTERED INTO A SALES AGREEMENT WITH COWEN AND COMPANY‍​.RECRO PHARMA - PURSUANT TO AGREEMENT, CO MAY SELL FROM TIME TO TIME, COMMON STOCK SHARES, $0.01 PAR VALUE/SHARE, WITH OFFERING PRICE OF UP TO $40 MILLION.  Full Article

Recro Pharma secures $100 million credit facility
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Recro Pharma Inc :Recro Pharma Inc secures $100 million credit facility.Recro Pharma Inc - ‍has secured a $100 million credit facility from funds managed by Athyrium Capital Management, LP​.Recro Pharma Inc - ‍proceeds from facility to refinance Recro's outstanding debt, pay $45 million milestone to alkermes upon approval of iv meloxicam 30mg by FDA​.  Full Article

Recro Pharma reports Q3 revenue $17.1 million
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Recro Pharma Inc :Recro Pharma reports third quarter 2017 financial results.Q3 revenue $17.1 million versus I/B/E/S view $13.7 million.Recro Pharma Inc - ‍Raising its guidance for 2017 revenue from a range of $60-$63 million to $65 million​.Recro Pharma Inc qtrly ‍revenues were $17.1 million versus $17.0 million​.Recro Pharma Inc - ‍As of September 30, 2017, Recro had cash, cash equivalents and short-term investments of $41.3 million​.  Full Article

Recro Pharma says offering of 6.50 mln shares priced at $6/share
Tuesday, 13 Dec 2016 

Recro Pharma Inc: Recro Pharma announces pricing of public offering of common stock .Says public offering of 6.50 million common shares priced at $6.00 per share.  Full Article

Photo

Recro Pharma shares plummet after FDA rejects non-opioid pain shot

Recro Pharma's shares dropped more than 50 percent on Thursday after the U.S. Food and Drug Administration declined to approve the drugmaker's non-opioid shot IV meloxicam, saying the pain-relieving effect did not meet expectations.